Cordova, E. | bioRxiv Science

bioRxiv2026

Detection of diverse coronaviruses, paramyxoviruses, and rhabdoviruses from cave-dwelling bats in Eastern Uganda

Bats harbor a diversity of viruses, some of which have the potential to impact human and livestock health. Caves in Eastern Uganda are commonly inhabited by bats in the genera Rhinolophus, Hipposideros, Myonycteris, and others. Human encroachment into these caves for shelter, hunting, mineral harvesting, and tourism poses a risk of exposure to infectious agents these bats may carry, yet little is known about the viruses present in these bats. From 2021 - 2023, 635 unique bats were captured in caves by mist net, with 69 bats resampled over the study for a total of 706 sampling instances. A total of 1,394 oral and rectal swabs were collected non-destructively and screened using molecular techniques for coronaviruses, paramyxoviruses, rhabdoviruses, flaviviruses, and filoviruses. Of these samples, 399 (56.5%) were collected during the rainy season and 307 (43.5%) during the dry season. Coronavirus RNA was detected in 59/706 (8.36%) of samples from Rhinolophus spp. (n = 35), Hipposideros caffer (n = 12), Myonycteris angolensis (n = 6), and Miniopterus spp. (n = 6). Six bats (0.85%) were positive for paramyxoviruses. Finally, (3 H. caffer, 1 M. angolensis, 1 Rhinolophus spp. and 1 Nycteris thebaica) 3 Rhinolophus bats were positive for rhabdoviruses (0.42%, all Rhinolophus spp.). No samples were positive for filovirus or flavivirus RNA. This project has generated novel data on the association of bat species and different viral strains present in these bats, advancing our knowledge of viral ecology and spillover risk at the human/bat interface.

genomics↗

bioRxiv2025

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer

Prostate cancer remains a leading cause of cancer-related mortality in men, with aggressive, treatment-emergent androgen receptor (AR)-indifferent subtypes, including double-negative prostate cancer (DNPC) and neuroendocrine prostate cancer (NEPC), posing major clinical challenges due to limited therapeutic options. NUAK family kinase 2 (NUAK2), an AMPK-related kinase, has been implicated in tumor growth and metastatic progression; however, its functional significance and therapeutic potential in advanced prostate cancer remain largely unexplored. Here, we identify NUAK2 as a therapeutically actionable kinase dependency in AR-indifferent prostate cancer. Transcriptomic analyses across independent patient cohorts demonstrated progressive upregulation of NUAK2 with disease progression, with the highest expression in NEPC. Immunohistochemical analysis of clinical specimens further confirmed elevated NUAK2 protein expression in NEPC relative to prostate adenocarcinoma. Genetic loss- and gain-of-function studies established NUAK2 as a functional dependency that promotes tumor cell proliferation, clonogenic growth, and tumor growth in vivo. Mechanistically, integrated proteomic analyses revealed that NUAK2 associates with spliceosomal and RNA-processing machinery, while NUAK2 perturbation induced widespread alterations in pre-mRNA splicing programs involving genes linked to mitotic regulation and oncogenic signaling. Pharmacologic studies identified trilaciclib (G1T-28), a clinically approved CDK4/6 inhibitor, as a functionally relevant NUAK2 inhibitor that directly engages NUAK2, suppresses tumor growth, and enhances the efficacy of platinum-based chemotherapy across multiple preclinical models. Collectively, these findings uncover NUAK2 as a previously unrecognized regulator of RNA splicing and therapeutic vulnerability in AR-indifferent prostate cancer and provide a rationale for repurposing G1T-28 and developing NUAK2-directed therapeutic strategies for aggressive, treatment-refractory prostate cancer.

cancer biology↗